Utilizing a PLASMIC score‐based approach in the management of suspected immune thrombotic thrombocytopenic purpura: a cost minimization analysis within the Harvard TMA Research Collaborative

Summary The PLASMIC score is a recently described clinical scoring algorithm that rapidly assesses the probability of severe ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) deficiency among patients presenting with microangiopathic haemolytic anaemia. Usi...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2019-08, Vol.186 (3), p.490-498
Main Authors: Upadhyay, Vivek A., Geisler, Benjamin P., Sun, Lova, Uhl, Lynne, Kaufman, Richard M., Stowell, Christopher, Makar, Robert S., Bendapudi, Pavan K.
Format: Article
Language:English
Subjects:
ADAM protein
ADAMTS13
Cost control
cost savings/effectiveness
Hematology
Hemolytic anemia
PLASMIC
Purpura
Thrombocytopenic purpura
Thrombospondin
Thrombotic thrombocytopenic purpura
Transfusion
TTP
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary The PLASMIC score is a recently described clinical scoring algorithm that rapidly assesses the probability of severe ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) deficiency among patients presenting with microangiopathic haemolytic anaemia. Using a large multi‐institutional cohort, we explored whether an approach utilizing the PLASMIC score to risk‐stratify patients with suspected immune thrombotic thrombocytopenic purpura (iTTP) could lead to significant cost savings. Our consortium consists of institutions with an unrestricted approach to ADAMTS13 testing (Group A) and those that require pre‐approval by the transfusion medicine service (Group B). Institutions in Group A tested more patients than those in Group B (P 
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.15932